接种SARS-CoV-2疫苗后接受乳腺检查的女性腋窝淋巴结增大:285例女性单中心经验
这项前瞻性单中心研究纳入2021年7月至10月间接受乳腺X线和超声检查的285例女性,按接种疫苗至成像间隔分为5个亚组,用超声评估腋窝淋巴结。14.4%(41/285)出现淋巴结病,在较年轻女性、接种Moderna疫苗者及接种后<6周检查者中更常见;作者结论认为接种后12周内出现淋巴结病是常见表现,尤其见于年轻女性和接种Moderna疫苗后,无需进一步评估。
要点
- 接种后12周内超声发现腋窝淋巴结病常见,尤其见于年轻女性及接种Moderna疫苗者。
- 最常见的病理特征是皮质增厚,其次是脂肪门完全或部分消失。
- 作者认为接种后12周内出现的淋巴结病无需进一步评估。
核心结论
- 接种后12周内出现淋巴结病是常见表现,尤其见于较年轻女性和接种Moderna疫苗后,作者认为无需进一步评估。
研究设计与样本
- 前瞻性单中心研究,纳入285例接受乳腺X线和乳腺超声的女性,按接种至成像间隔分为<6周、7-8周、9-10周、11-12周、>12周共5个亚组,以超声评估腋窝淋巴结。
关键影像表现/征象
- 最常见的病理特征为皮质增厚,其次为脂肪门完全或部分消失。
- 41/285(14.4%)女性显示淋巴结病,其年龄(46.9±11.6岁)显著小于临界淋巴结病女性(54.0±11.9岁)和无淋巴结病女性(57.3±11.9岁)(p<.001)。
- 淋巴结病和临界淋巴结病在接种Moderna疫苗的女性及接种后<6周检查的亚组中更常见(p<0.001)。
诊断标准与关键数值
- 淋巴结病在接种Moderna疫苗女性及接种后<6周检查亚组中更常见(p<0.001)。
- 41/285(14.4%)女性显示淋巴结病,年龄46.9±11.6岁,显著小于临界淋巴结病女性54.0±11.9岁和无淋巴结病女性57.3±11.9岁(p<.001)。
临床应用与阅片要点
- 作者认为接种后12周内出现的淋巴结病无需进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To assess the incidence of axillary lymphadenopathy over established time ranges after COVID-19 vaccination and lymph node pathologic features (i.e. size increase and qualitative characteristics) in subjects undergoing axillary evaluation during a breast imaging examination.
METHODS AND MATERIALS: The institutional review board approved this prospective study.
INCLUSION CRITERIA: women undergoing mammography and breast ultrasound between July and October 2021; information about the COVID-19 vaccine and infection, if any.
EXCLUSION CRITERIA: known metastatic lymphadenopathy. Participants were divided into 5 subgroups according to time between vaccine and imaging: < 6 weeks; 7-8 weeks; 9-10 weeks; 11-12 weeks; > 12 weeks. Evaluation of axillary lymph nodes was performed with ultrasound. Descriptive statistical analysis was performed. p < 0.05 was considered significant.
RESULTS: A total of 285 women were included. Most of the patients underwent Moderna vaccine (n = 175, 61.4%). 63/285 patients had a previous history of breast cancer (22.1%). 13/17 (76.5%) patients with previous COVID-19 infection had no previous history of cancer, whereas 4/17 had a previous history of cancer (p < .001). 41/285 (14.4%) women showed lymphadenopathy, and they were significantly younger (46.9 ± 11.6 years) than women with borderline (54.0 ± 11.9 years) or no lymphadenopathy (57.3 ± 11.9 years) (p < .001). Lymphadenopathy and borderline lymphadenopathy were more frequently observed in the Moderna-vaccinated women and in the subgroup of patients evaluated < 6 weeks after vaccination (p < 0.001). The most common pathologic feature was cortical thickening, followed by complete or partial effacement of fatty hilum.
CONCLUSION: A lymphadenopathy within 12 weeks after vaccination is a common finding particularly in younger women and after Moderna vaccine and no further assessment should be required.
引用
- Marcon M, Catanese C, Scarano AL, et al. Axillary lymph nodes enlargement after Sars-CoV-2 vaccine in patients undergoing breast examination: a single-centre experience in 285 women. Radiol Med. 2023. PMID: 37626156. doi:10.1007/s11547-023-01696-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。